Xalud Therapeutics is a clinical-stage biotechnology company based in San Francisco, CA, that is focused on developing a non-viral plasmid DNA-delivered gene therapy platform to treat chronic inflammatory diseases by restoring homeostasis in the immune system. Their lead candidate, XT-150, is a locally injectable gene therapy that expresses a modified version of interleukin-10 (IL-10), a potent cytokine that regulates multiple inflammatory pathways.
Their mission is to transform the treatment of chronic inflammatory diseases by addressing the underlying cause of the disease rather than just managing symptoms, with the goal of improving patient lives. Xalud's proprietary non-viral gene therapy platform offers adaptability and the potential to safely deliver transgenes to patients with a wide range of chronic inflammatory, neurological, and autoimmune diseases, expanding the capabilities of gene therapy beyond rare conditions to more prevalent diseases.
Generated from the website